Myeloproliferative Neoplasms (MPNs)

Myeloproliferative disorders are a group of rare illnesses that cause blood cells in the bone marrow, including red blood cells, white blood cells, and platelets, to grow and develop abnormally.

Myeloproliferative disorders occur when the body produces too many of one or more types of blood cells. However, the reason for this remains unknown. Researchers believe that genetics and/or the environment may play a role in the development of these disorders.

Myeloproliferative disorders are serious medical conditions. Complications of these disorders may be fatal. A person's survival rate depends on the type of myeloproliferative disorder he/she has, as well as the severity of his/her illness.

Although there is no cure for myeloproliferative disorders, treatment may help patients live several years after they are diagnosed.

Previous Section Next Section

Clinical Trials

Clinical trials are research studies that evaluate a new medical approach, device, drug, or other treatment. As a Stanford Health Care patient, you may have access to the latest, advanced clinical trials.

Open trials refer to studies currently accepting participants. Closed trials are not currently enrolling, but may open in the future.

Before beginning treatment, ask your doctor about any clinical trials you should consider. Learn more about clinical trials for cancer patients.

Clinical trial eligibility flowcharts

Eligibility flowcharts map clinical trials to specific types of cancers to determine if a participant is eligible for the particular clinical trial. View all hematology eligibility flowcharts at the Stanford Cancer Institute.

Open Trials Closed Trials

Clinics for Myeloproliferative Neoplasms